1. Crystal structure of perovskite
[3] 2. (a) Schematic diagram of defects in perovskite film
[10]; (b) Transition energy levels of intrinsic acceptors and intrinsic donors in MAPbI
3[15]; (c) Schematic diagram of passivation strategies of defects
3. (a) Energy level alignment of MAPbI
3 film and PbI
2[21]; (b) Scanning electron microscopy(SEM) image of MAPbI
3 film with PbI
2 wrapping the perovskite grain
[21]; (c) Schematic diagram of mechanism for PbI
2 passivation in CH
3NH
3PbI
3 film
[21]; (d) Schematic diagram of mechanism for K
+ passivation
[27]; (e) Photoluminescence quantum efficiency(PLQE) of passivated perovskite thin films with increasing fraction of potassium
[27]; (f) Current density-voltage curves of the best-performing solar cells with (Cs, MA, FA) Pb(I
0.4Br
0.6)
3 absorbers without and with potassium passivation
[27]; (g) Stability for the Cs
10Rb
5FAPbI
3 device
[28]; (h) UV-Vis absorption spectra of the PCBM-perovskite hybrid solution
[34] 4. (a) Schematic diagram of MAPbI
3 perovskite films crystallization processes
[39]; (b) Chemical structure of caffeine
[41]; (c) Fourier Transform infrared spectroscopy (FT-IR) spectra and magnified fingerprint regions of pure caffeine, caffeine-MAPbI
3, and the pristine MAPbI
3 films
[41]; (d) FT-IR spectra of PbI
2-PMMA and pristine PMMA films
[43]; (e) Top view SEM images of perovskite films without (left) and with (right) 0.6 mg∙mL
-1 TDZDT
[44]; (f) Photographs and schematic process for formation of FAPbI
3 perovskite films by using NMP
[45]; (g) Chemical structures of SP1, SP2 and SP3
[48]; (h) Schematic illustration of the passivation process of donor-acceptor molecules for under-coordinated Pb
2+ cations
[48]; (i) Statistic trap densities for the control and passivated perovskite films derived from the space charge limit current (SCLC) measurement
[48] 5. (a) Schematic illustration of two neighbouring grain structures crosslinked by butylphosphonic acid 4-ammonium chloride (4-ABPACl)
[50]; (b) Surface SEM images of pristine (control) and 4-ABPA-anchored (CH
3NH
3PbI
3-ABPA) perovskite films deposited on mp-TiO
2/FTO substrates
[50]; (c) Variations of X-ray diffraction(XRD) spectra patterns of the FASnI
3-EDAI
2 1% film at different duration of storage
[51]; (d) Schematic diagram of RATZ passivation
[53]; (e) Schematic diagram of thiophene passivation
[55]; (f) Theoretical model of perovskite with molecular surface passivation of PbI antisite with theophylline
[61]; (g) Statistical photovoltaic parameters of PCE depending on pK
a[64] Additive | Perovskite | Functional group | PCE | Stability | Ref. |
---|
PbI2 | (FAPbI3)1-x(MAPbBr3)x | Pb2+ | 21.6% | - | [22] | MACl | (Cs,FA,MA)PbBrxI1-x | MA+ | 21.65% | N2, rt, 500 h, 96%
| [24] | NaCl | (FAPbI3)1-x(MAPbBr3)x | Na+ | 20.2% | - | [26] | RbI | Rb5Cs10FAPbI3 | Rb+ | 20.35% | N2, rt, 1000 h,>98%
| [28] | MnCl2 | CsPbI2Br
| Mn2+ | 13.47% | 25 ℃, 25%-35% RH, 35 d, 97% | [30] | NiCl2 | MAPbI3 | Ni2+ | 20.61% | - | [31] | ZnI2 | CsPbI2Br
| Zn2+ | 12.16% | N2, 60% RH, 500 h, 76%
| [32] | bis-PCBM | (FAI)0.81(PbI2)0.85(MABr)0.15(PbBr2)0.15 | Fullerene | 20.8% | Air, 65 ℃, 60% RH, 44 d, 90.1% | [35] | Caffeine | MAPbI3 | O donor | 20.25% | N2, 85 ℃, 1300 h, 86%
| [41] | PVP | CH3NH3PbI3 | N donor | 20.2% | N2, 2500 h, 85%
| [42] | PMMA | (FAI)0.81(PbI2)0.85(MAPbBr3)0.15 | O donor | 21.6% | Air, 60 d, 96.7% | [43] | NMP | FAPbI3 | O donor | 20.19% | - | [45] | D4TBP | Cs0.05FA0.81MA0.14PbI2.55Br0.45 | N donor | 21.4% | - | [47] | SP3 | MAPbI3 | O,S donor | 20.43% | Air, 30% RH, 30 d,86% | [48] | EDAI2 | FASnI3 | N donor | 8.9% | Air, 20 ℃, 50% RH, 2000 h, >90% | [51] | RATZ | MAPbI3 | N donor | 20.03% | Air, (40±5)% RH, 3500 h, 80% | [53] |
|
Table 1. Additives during perovskite formation and their device performance
Additive | Perovskite | Functional group | PCE | Stability | Ref. |
---|
MMI | MAPbI3 | N, S donor | 20.10% | N2, 2184 h, 94%
| [59] | P3HT | CsPbI2Br
| S donor | 12.02% | N2, 960 h, 90%
| [60] | Theophylline | (FAPbI3)x(MAPbBr3)1-x | N, O donor | 22.6% | N2, 40 ℃, 30%-40% RH, 500 h, >90%
| [61] | 2-MP | MAPbI3 | N, S donor | 20.28% | Air, 60%-70% RH, 60 d, 93% | [62] | TPFP | Cs0.05FA0.8MA0.15Pb(I0.83Br0.17)3 | P donor | 22.02% | 75% RH, 14 d, 63% | [63] | CYCl | FAPbI3 | N donor | 24.98% | (22±5) ℃, (25±10)% RH, 1300 h, 91% | [64] | FEAI | Cs0.06 FA1.38MA0.06 Pb1.6 I4.7 | 2D perovskite | 22.1% | Air, 40% RH, 1000 h, 90% | [67] | C6Br
| (FAPbI3)0.92(MAPbBr3)0.08 | 2D perovskite | 23.4% | - | [68] | PEAI | FA1-xMAxPbI3 | 2D perovskite | 23.32% | N2, 85 ℃, 500 h, >80%
| [70] |
|
Table 2. Post-treatment additives and their device performance